Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders. It is dedicated to improving the lives of patients and their families by developing treatments for conditions like Huntington's disease and ALS.
- Category
- Biopharmaceuticals
- Stage
- Series B
- Employees
- 58
- HQ
- Naarden, Netherlands
- Founded
- 2018
- Funding
- $144M